Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Anjana Anilkumar Sithara"'
Autor:
Daisuke Ogiya, Zuzana Chyra, Sigitas J. Verselis, Morgan O’Keefe, Jacquelyn Cobb, Ivane Abiatari, Srikanth Talluri, Anjana Anilkumar Sithara, Teru Hideshima, Michael P. Chu, Roman Hájek, David M. Dorfman, Linda M. Pilarski, Kenneth C. Anderson, Sophia Adamia
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Novel drug discoveries have shifted the treatment paradigms of most hematological malignancies, including multiple myeloma (MM). However, this plasma cell malignancy remains incurable, and novel therapies are therefore urgently needed. Whole
Externí odkaz:
https://doaj.org/article/0720ebfef4374a3d981cb2d875066c2e
Autor:
David Zihala, Tomas Jelinek, Tereza Sevcikova, Anjana Anilkumar Sithara, Veronika Kapustova, Daniel Bilek, Hana Sahinbegovic, Tereza Popkova, Hana Plonkova, Lucie Broskevicova, Ondrej Venglar, Jan Vrana, Vladimir Zidlik, Martin Havel, Zdenek Koristek, Matous Hrdinka, Zuzana Chyra, Michal Simicek, Roman Hajek
Publikováno v:
HemaSphere, Vol 7, p e003730a (2023)
Externí odkaz:
https://doaj.org/article/554b03b769da464b9aa0e4b59f091fed
Autor:
Marcello Turi, Anjana Anilkumar Sithara, Lucie Hofmanová, David Žihala, Dhwani Radhakrishnan, Alexander Vdovin, Sofija Knápková, Tereza Ševčíková, Zuzana Chyra, Tomas Jelínek, Michal Šimíček, Annamaria Gullà, Kenneth Anderson, Roman Hájek, Matous Hrdinka
Publikováno v:
HemaSphere, Vol 7, p e4265786 (2023)
Externí odkaz:
https://doaj.org/article/239e6e68120e449e9ad5ad88f35cc6bf
Autor:
Marcello Turi, Anjana Anilkumar Sithara, Lucie Hofmanová, David Žihala, Dhwani Radhakrishnan, Alexander Vdovin, Sofija Knápková, Tereza Ševčíková, Zuzana Chyra, Tomáš Jelínek, Michal Šimíček, Annamaria Gullà, Kenneth Carl Anderson, Roman Hájek, Matouš Hrdinka
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 6; Pages: 5623
During innate immune responses, myeloid differentiation primary response 88 (MyD88) functions as a critical signaling adaptor protein integrating stimuli from toll-like receptors (TLR) and the interleukin-1 receptor (IL-1R) family and translates them
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cd7d918bd07176a6fa599ba88f905ca
Autor:
Lucie Broskevicova, Kateřina Growková, Jana Filipova, Jiří Minařík, Roman Hájek, Ludek Pour, Giovanni Stracquadanio, Lucie Rihova, Fedor Kryukov, Juli R. Bagó, Lubica Harvanova, Zuzana Chyra, Lucie Cerna, Michal Simicek, Vladimir Maisnar, Martina Zatopkova, Renata Bezdekova, Matous Hrdinka, David Žihala, Alexandra Jungova, Viola Fanfani, Tereza Sevcikova, Jana Smejkalová, Tereza Popkova, Anjana Anilkumar Sithara, Tomas Jelinek
Publikováno v:
Zátopková, M, Ševčíková, T, Fanfani, V, Chyra, Z, Rihova, L, Bezdekova, R, Žihala, D, Growková, K, Filipova, J, Černá, L, Broskevičová, L, Kryukov, F, Minařík, J, Smejkalová, J, Maisnar, V, Harvanová, L, Pour, L, Jungova, A, Popková, T, Bago, J R, Anilkumar Sithara, A, Hrdinka, M, Jelinek, T, Šimíček, M, Stracquadanio, G & Hajek, R 2021, ' Mutation landscape of multiple myeloma measurable residual disease : identification of targets for precision medicine ', Blood Advances . https://doi.org/10.1182/bloodadvances.2020003876
Blood Advances
Blood Advances
Multiple myeloma (MM) measurable residual disease (MRD) persisting after treatment is an adverse prognostic factor for progression free survival (PFS) and overall survival.1Genomic mutations occurred in the remaining clonal aberrant plasma cells (A-P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::416410420e5d98efe4fb72c3bcc142a6
https://doi.org/10.1182/bloodadvances.2020003876
https://doi.org/10.1182/bloodadvances.2020003876
Autor:
Tomas Jelinek, Renata Bezdekova, David Zihala, Tereza Sevcikova, Anjana Anilkumar Sithara, Lenka Pospisilova, Sabina Sevcikova, Petra Polackova, Martin Stork, Zdenka Knechtova, Ondrej Venglar, Veronika Kapustova, Tereza Popkova, Ludmila Muronova, Zuzana Chyra, Matous Hrdinka, Michal Simicek, Juan-Jose Garcés, Noemi Puig, Maria-Teresa Cedena, Artur Jurczyszyn, Jorge J. Castillo, Miroslav Penka, Jakub Radocha, Maria Victoria Mateos, Jesús F. San-Miguel, Bruno Paiva, Ludek Pour, Lucie Rihova, Roman Hajek
Publikováno v:
Journal of clinical oncology
PURPOSE Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fd84d5440331b207f2388f3f792960e
https://pubmed.ncbi.nlm.nih.gov/36315921
https://pubmed.ncbi.nlm.nih.gov/36315921
Autor:
Anjana Anilkumar Sithara, Devi Priyanka Maripuri, Keerthika Moorthy, Sai Sruthi Amirtha Ganesh, Philge Philip, Shayantan Banerjee, Malvika Sudhakar, Karthik Raman
Publikováno v:
NAR Genomics and Bioinformatics. 4
Despite the tremendous increase in omics data generated by modern sequencing technologies, their analysis can be tricky and often requires substantial expertise in bioinformatics. To address this concern, we have developed a user-friendly pipeline to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b7d92f5d75c758ebc35f4f601b0da2
https://doi.org/10.1093/nargab/lqac053
https://doi.org/10.1093/nargab/lqac053
Autor:
Shayantan Banerjee, Malvika Sudhakar, Philge Philip, Keerthika Moorthy, Devi Priyanka Maripuri, Anjana Anilkumar Sithara, Karthik Raman, Sai Sruthi Amirtha Ganesh
Despite the tremendous increase in omics data generated by modern sequencing technologies, their analysis can be tricky and often requires substantial expertise in bioinformatics. To address this concern, we have developed a user-friendly pipeline to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7876da88c410c251cd2d87512e41c3c7
https://doi.org/10.1101/2021.09.18.460896
https://doi.org/10.1101/2021.09.18.460896
Autor:
Lucie Huvarova, Tereza Sevcikova, Ludmila Muronova, Veronika Kapustová, Ondrej Venglar, Lucie Broskevicova, Anjana Anilkumar Sithara, Zdenek Koristek, David Zihala, Tomas Jelinek, Michal Simicek, Roman Hájek, Jan Vrana
Publikováno v:
Blood. 138:2764-2764
Introduction: Daratumumab (Dara) is an anti-CD38 monoclonal antibody representing a novel treatment agent for multiple myeloma (MM). Nonetheless, several studies have reported a Dara-related impairment of CD34+ hematopoietic stem cell (HSC) mobilizat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5d9b20eb720180fcb4fcdc3c2a08c70
https://doi.org/10.1182/blood-2021-150360
https://doi.org/10.1182/blood-2021-150360
Autor:
Zdenek Koristek, Anjana Anilkumar Sithara, Lucie Broskevicova, Tereza Popkova, Martin Havel, Tereza Sevcikova, Veronika Kapustová, Roman Hájek, Vladimir Zidlik, Juli R. Bagó, Jan Vrana, Hana Plonkova, Hana Sahinbegovic, Tomas Jelinek, David Zihala, Michal Simicek
Publikováno v:
Blood. 138:2680-2680
I ntroduction Extramedullary disease (EMD) is a less frequent manifestation of multiple myeloma (MM), where MM plasma cells become independent of the bone marrow (BM) microenvironment and infiltrate other tissues and organs. The incidence of EMD is i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4283a09c7f0c4868ffb463b30b63d67
https://doi.org/10.1182/blood-2021-150876
https://doi.org/10.1182/blood-2021-150876